Clinical trials: PCNSL, open to volunteers
CNS Lymphoma
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
The purpose of this study is to is to determine the effects (good and bad) of Zanubrutinib in Combination with Pola-R-CHP and High-dose Methotrexate in patients with Secondary Central Nervous System (CNS) Lymphoma.
- Trial name
- NCT06730542
- Testing
- Zanubrutinib, Methotrexate, Polatuzumab Vedotin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Juan P. Alderuccio, MD
Primary Central Nervous System (CNS) Lymphoma
R-PMDT Regimen in Newly Diagnosed PCNSL
A total of six cycles of the R-PMDT regimen (rituximab, pirtobrutinib, high-dose methotrexate, dexamethasone, and thiotepa) will be administered to patients with newly diagnosed primary central nervous system lymphoma (PCNSL).
- Trial name
- NCT07604987
- Testing
- R-PMDT
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Zou Dehui
Lymphomas
Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study
This phase II clinical trial is designed to evaluate a novel combination treatment for patients with newly diagnosed central nervous system lymphoma (CNSL) who are not candidates for stem cell transplantation.
- Trial name
- NCT07002099
- Testing
- Selinexor + High-dose Methotrexate + Rituximab + WBRT
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Primary Central Nervous System Lymphoma (PCNSL)
Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL
This study aims to evaluate the efficacy and safety of the VPX regimen, a novel combination of teniposide, PD-1 monoclonal antibody and selinexor, in patients with relapsed/refractory (R/R) primary central nervous system lymphoma…
- Trial name
- VPX (NCT07074470)
- Testing
- Induction therapy-2 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor), Consolidation therapy with ASCT after TB (Thiotepa plus Busulfan) preconditioning, Consolidation therapy-4 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Primary Central Nervous System Lymphoma
Methotrexate Early Toxicity Monitoring
High-dose methotrexate (MTX) is the main componement of first line treatment in primary central nervous system lymphoma. Renal toxicity is the main dose limiting toxicity because of major MTX elimination by the kidneys.
- Trial name
- METoxiM (NCT07406230)
- Testing
- methotrexate plasmatic dosing
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma
This phase Ib trial tests the safety and side effects of glofitamab after pre-treatment with obinutuzumab and how well they work in treating patients with central nervous system (CNS) lymphoma.
- Trial name
- NCT06922604
- Testing
- Biospecimen Collection, Computed Tomography, Glofitamab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Primary CNS Lymphoma
Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.
After standard treatment of primary central nervous system lymphoma (PCNSL), high-dose methotrexate induction therapy, and consolidation therapy, most patients reach complete remission, but within the first 6 months, 35-60% of…
- Trial name
- Lemon-C (NCT04627753)
- Testing
- Rituximab, lenalidomide
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Kim, Seok Jin
Central Nervous System Lymphoma
Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma
This is a prospective single arm, phase II clinical trial to observe the efficacy and safety of orelabrutinib combined with pemetrexed in the treatment for patients with relapsed/refractory central nervous system lymphoma.
- Trial name
- NCT05209620
- Testing
- ICP-022, Pemetrexed
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
PCNSL (Primary CNS Lymphoma), Central Nervous System Lymphoma
Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System Lymphoma
This study is being done to find out whether the combination of glofitamab, gemcitabine and oxaliplatin (GemOx) works and is safe in people whose lymphoma has come back or has not responded to previous treatment and has spread to…
- Conditions
- PCNSL (Primary CNS Lymphoma), Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma (SCNSL)
- Trial name
- NCT07888621
- Testing
- Glofitamab, Gemcitabine, Oxaliplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Chronic Lymphocytic Leukemia, Lymphomas Non-Hodgkin's B-Cell
Long-term Follow-up Study of Patients Receiving CAR-T Cells
This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital.
- Conditions
- Chronic Lymphocytic Leukemia, Lymphomas Non-Hodgkin's B-Cell, Lymphoma, Small Lymphocytic, Mantle Cell Lymphoma
- Trial name
- NCT03375619
- Testing
- Long-Term Follow-Up of Participants who Received CAR-T cells
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Medical College of Wisconsin
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL)
- Trial name
- NCT04830137
- Testing
- NX-2127
- Where
- 16 sites in United States
- Volunteers
- 248 people
- Sponsor
- Nurix Therapeutics, Inc.
Primary Central Nervous System Lymphoma (PCNSL), CNS Lymphoma Treatment
Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma
High-dose methotrexate (HD-MTX) remains the foundation of treatment for primary central nervous system lymphoma (PCNSL), but outcomes are suboptimal.
- Trial name
- NCT06946407
- Testing
- Rituximab, Methotrexate, and Thiotepa (R-MT) Induction Followed by Etoposide and Cytarabine (EA) Consolidation
- Where
- China
- Volunteers
- 41 people
- Sponsor
- FengYan Jin
Primary CNS Lymphoma
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma
This phase I trial evaluates the feasibility of using hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing patients with primary central nervous system lymphoma.
- Trial name
- NCT04656431
- Testing
- Hyperpolarized pyruvate (13C), Magnetic resonance imaging (MRI)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- James Rubenstein
CNS Lymphoma, Primary Central Nervous System Lymphoma
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
This is a single arm open-label multicenter phase I/II investigation of combination lenalidomide/Tafasitamab in patients with relapsed central nervous system (CNS) lymphoma.
- Conditions
- CNS Lymphoma, Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
- Trial name
- NCT05351593
- Testing
- Tafasitamab, Lenalidomide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- James Rubenstein
Cerebral Lymphoma
Improving Safety and Accuracy of Stereotactic Brain Biopsies in Primary Central Nervous System Lymphoma.
Primary central nervous system lymphoma (PCNSL) is an aggressive extranodal non- Hodgkin lymphoma exclusively localized into the nervous system.
- Trial name
- NCT06263361
- Testing
- MRI imaging, Cerebral biopsy
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- IRCCS San Raffaele
Primary Central Nervous System Lymphoma
Rapid Diagnosis and Treatment Response Monitoring of Primary CNS Lymphoma Using CSF ctDNA Liquid Biopsy
The incidence of primary central nervous system lymphoma (PCNSL) has increased steadily, and the disease often progresses rapidly, with many patients presenting in critical condition.
- Trial name
- NCT07851363
- Testing
- HD-MTX-based chemotherapy, BTK inhibitor
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Xiaohui Ren
Central Nervous System Lymphoma
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
The purpose of this clinical trial is to learn if drugs loncastuximab tesirine and rituximab (lonca-R) after stereotactic radiosurgery are safe and effective for treatment of central nervous system lymphomas.
- Trial name
- SOLAR (NCT06607549)
- Testing
- Loncastuximab tesirine and rituximab (Lonca-R)
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Primary Central Nervous System Lymphoma
Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma
This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of Rituximab, Lenalidomide combined with high-dose Methotrexate and Temozolomide (RL-MT) in the first-line treatment for…
- Trial name
- NCT04737889
- Testing
- Rituximab, Lenalidomide, Methotrexate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
Primary Central Nervous System Lymphoma
Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104)
A double-blind, randomized phase II comparative trial will evaluate the superiority of the investigational treatment (tirabrutinib maintenance therapy) over standard care (observation with placebo) in terms of progression-free…
- Trial name
- TIMELY-pII (NCT06940791)
- Testing
- Tirabrutinib
- Where
- Japan
- Volunteers
- 92 people
- Sponsor
- Kyorin University
Primary Central Nervous System Lymphoma
Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
This is a three-arm, multicenter, randomized controlled trial. Eligible participants will be randomized to one of three induction regimens via stratified block randomization at a 2:2:1 ratio.
- Trial name
- NCT07185373
- Testing
- Teniposide, Orelabrutinib, MTX
- Where
- 15 sites in China
- Volunteers
- 215 people
- Sponsor
- Huashan Hospital